Biotechnology
Checking In on 2 Small Biotech Names That Had Big Quarters
Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
Investing in Small Biotechs? Check Out the CFO First
They're the most important executive at most small developmental or early commercialization concerns.
Big Pharma Sees Pockets of Recent Insider Buying
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
Swinging for the Small-Cap Biotech Fences Requires Accepting Strikeouts
Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.
Simulations Plus Can't Go Up Forever, so It's Time to Book the Profits
Parabolic moves can be alluring, but if you are long on SLP, consider how far it can fall from here.
While No Magic Pill, Mylan Deal Might Just Revive Drugmaker
The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.
Anika Therapeutics Gets a Quant Upgrade to Buy, Adding to Its Technical Breakout
Let's check out the latest charts and indicators.
Pfizer Deal Might Be Good Treatment for Mylan
But this off-patent tie-up comes with some questions -- such as why are so many Mylan executives hanging on?
A Look at Mylan's New Post-Merger Management
What new management means for Mylan shareholders moving forward.
2 Promising $5 Biotech Stocks to Consider on Recent News
Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.